Abstract:The Wells score and the revised Geneva score are two most commonly used clinical rules for excluding pulmonary embolism (PE). In this study, we aimed to assess the diagnostic accuracy of these two rules; we also compared the diagnostic accuracy between them. We searched PubMed and Web of science up to April 2015. Studies assessed Wells score and revised Geneva score for diagnosis suspected PE were included. The summary area under the curve (AUC) and the 95 % confidence interval (CI) were calculated. Eleven stu… Show more
“…Our study did not consider other validated prediction rules. However, a recent meta‐analysis comparing the Ws to the revised Geneva score demonstrated a superior accuracy of the former . In a meta‐analysis by Lucassen et al., the sensitivity of the dichotomized Ws was close to that obtained in our study, whereas the specificity was superior.…”
“…Our study did not consider other validated prediction rules. However, a recent meta‐analysis comparing the Ws to the revised Geneva score demonstrated a superior accuracy of the former . In a meta‐analysis by Lucassen et al., the sensitivity of the dichotomized Ws was close to that obtained in our study, whereas the specificity was superior.…”
“…Wells score is a well-validated test and should be calculated in all patients where PE is a potential diagnosis. Other probability scoring tools such as the revised Geneva score have also been well validated [18]. The British Society clinical probability score although not well validated has the advantage of simplicity [19].…”
“…Because of increasing population age, especially in Western countries, diagnosis and treatment of APE has become a major challenge (1). Risk stratification with clinical scoring systems such as Wells score or revised Geneva score is of value, but the sensitivity of 64-79% and 44-74%, respectively; limit their use in ruling out the diagnosis (5). D-dimer, a fibrin degradation product, has a reported sensitivity of 95% and specificity of 36%, and is used to exclude APE in low and medium risk patients (6,7).…”
Background: Acute pulmonary embolism (APE) is a potentially fatal condition, and making a timely diagnosis can be challenging. Computed tomography pulmonary angiography (CTPA) has become the modality of choice, and this contributes to the increasing load on emergency room CT scanners. Our purpose was to investigate whether an elevated d-dimer cut-off could reduce the demand for CTPA while maintaining a high sensitivity and negative predictive value (NPV).
Methods:We retrospectively reviewed all patients referred for CTPA with suspicion of APE in 2012, and collected d-dimer values and CTPA results. We investigated the diagnostic performance of d-dimer using a 0.5 mg/L cut-off and an age adjusted cut-off. We also evaluated a new and elevated cut-off. Cases were categorized according to their CTPA result into: no embolism, peripheral embolism, lobar embolism and central embolism.
Finally we investigated a possible correlation between d-dimer values and location of embolism.Results: We included 1,051 CTPAs, from which 216 (21%) showed pulmonary embolism. There were concomitant d-dimer analyses in 822 CTPA examinations. The current 0.5 mg/L cut-off achieved a sensitivity and NPV of 99%. The age-adjusted cut-off achieved a sensitivity and NPV of 98%, and our suggested cut-off of 0.9 mg/L achieved a sensitivity and NPV of 97%.
Conclusions:We conclude that the elevated d-dimer cut-off of 0.9 mg/L achieved a high sensitivity and NPV, while reducing the number of CTPA by 27%. The correlation between d-dimer values and location of embolisms supports the suggestion of an elevated d-dimer value.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.